Genetic Determinants of Ototoxicity During and After Childhood Cancer Treatment: Protocol for the PanCareLIFE Study

Journals

1. Clemens E, Broer L, Langer T, Uitterlinden A, de Vries A, van Grotel M, Pluijm S, Binder H, Byrne J, Broeder E, Crocco M, Grabow D, Kaatsch P, Kaiser M, Kenborg L, Winther J, Rechnitzer C, Hasle H, Kepak T, van der Kooi A, Kremer L, Kruseova J, Kuehni C, van der Pal H, Parfitt R, Deuster D, Matulat P, Spix C, Tillmanns A, Tissing W, Maier L, am Zehnhoff-Dinnesen A, Zolk O, van den Heuvel-Eibrink M. Genetic variation of cisplatin-induced ototoxicity in non-cranial-irradiated pediatric patients using a candidate gene approach: The International PanCareLIFE Study. The Pharmacogenomics Journal 2020;20(2):294 View
2. Langer T, Clemens E, Broer L, Maier L, Uitterlinden A, de Vries A, van Grotel M, Pluijm S, Binder H, Mayer B, von dem Knesebeck A, Byrne J, van Dulmen-den Broeder E, Crocco M, Grabow D, Kaatsch P, Kaiser M, Spix C, Kenborg L, Winther J, Rechnitzer C, Hasle H, Kepak T, van der Kooi A, Kremer L, Kruseova J, Bielack S, Sorg B, Hecker-Nolting S, Kuehni C, Ansari M, Kompis M, van der Pal H, Parfitt R, Deuster D, Matulat P, Tillmanns A, Tissing W, Beck J, Elsner S, am Zehnhoff-Dinnesen A, van den Heuvel-Eibrink M, Zolk O. Association of candidate pharmacogenetic markers with platinum-induced ototoxicity: PanCareLIFE dataset. Data in Brief 2020;32:106227 View
3. Langer T, Clemens E, Broer L, Maier L, Uitterlinden A, de Vries A, van Grotel M, Pluijm S, Binder H, Mayer B, von dem Knesebeck A, Byrne J, van Dulmen-den Broeder E, Crocco M, Grabow D, Kaatsch P, Kaiser M, Spix C, Kenborg L, Winther J, Rechnitzer C, Hasle H, Kepak T, van der Kooi A, Kremer L, Kruseova J, Bielack S, Sorg B, Hecker-Nolting S, Kuehni C, Ansari M, Kompis M, van der Pal H, Parfitt R, Deuster D, Matulat P, Tillmanns A, Tissing W, Beck J, Elsner S, am Zehnhoff-Dinnesen A, van den Heuvel-Eibrink M, Zolk O. Usefulness of current candidate genetic markers to identify childhood cancer patients at risk for platinum-induced ototoxicity: Results of the European PanCareLIFE cohort study. European Journal of Cancer 2020;138:212 View
4. Landier W, Cohn R, van den Heuvel-Eibrink M. Hearing and Other Neurologic Problems. Pediatric Clinics of North America 2020;67(6):1219 View
5. Kaatsch P, Byrne J, Grabow D. Managing a Pan-European Consortium on Late Effects among Long-Term Survivors of Childhood and Adolescent Cancer—The PanCareLIFE Project. International Journal of Environmental Research and Public Health 2021;18(8):3918 View
6. Meijer A, Diepstraten F, Langer T, Broer L, Domingo I, Clemens E, Uitterlinden A, de Vries A, van Grotel M, Vermeij W, Ozinga R, Binder H, Byrne J, van Dulmen-den Broeder E, Garrè M, Grabow D, Kaatsch P, Kaiser M, Kenborg L, Winther J, Rechnitzer C, Hasle H, Kepak T, Kepakova K, Tissing W, van der Kooi A, Kremer L, Kruseova J, Pluijm S, Kuehni C, van der Pal H, Parfitt R, Spix C, Tillmanns A, Deuster D, Matulat P, Calaminus G, Hoetink A, Elsner S, Gebauer J, Haupt R, Lackner H, Blattmann C, Neggers S, Rassekh S, Wright G, Brooks B, Nagtegaal A, Drögemöller B, Ross C, Bhavsar A, am Zehnhoff-Dinnesen A, Carleton B, Zolk O, van den Heuvel-Eibrink M. TCERG1L allelic variation is associated with cisplatin-induced hearing loss in childhood cancer, a PanCareLIFE study. npj Precision Oncology 2021;5(1) View
7. Xu Y, Huang C, Liu J, Xu Y, Yang H. Circulating IL-17 reduces the risk of cisplatin-induced hearing loss in children: a bidirectional two-sample Mendelian randomization study. Scientific Reports 2023;13(1) View

Books/Policy Documents

1. Kleinjung T, Langguth B. The Behavioral Neuroscience of Tinnitus. View
2. Tillmanns A, Lanvers-Kaminsky C, Parfitt R, Meijer A, Tóth M, Münscher A, Beck J, van den Heuvel-Eibrink M, am Zehnhoff-Dinnesen A. Late Treatment Effects and Cancer Survivor Care in the Young. View